Aethlon Medical to Present at Life Sciences Investor Forum

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Mar 06 2026

0mins

AEMD+4.76%Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

Aethlon Medical Inc. shares rose by 14.50% in pre-market trading as the stock crossed above its 5-day SMA, indicating positive momentum.

The company will present at the Life Sciences Investor Forum on March 12, 2026, where CEO Jim Frakes will discuss ongoing clinical trials, including the active progression of Cohort 2 in the Australian oncology trial. This participation is expected to enhance investor confidence and visibility, particularly with advancements in their extracellular vesicle research platform and the potential of the Hemopurifier as a multi-indication therapeutic approach.

This event is likely to attract significant attention from investors, potentially leading to increased interest in Aethlon's research and development efforts, as well as its ongoing technology developments aimed at broadening clinical applications.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy AEMD?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on AEMD

About AEMD

Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Aethlon Medical Monitors Ebola Outbreak Developments

4 days agoPRnewswire

Ebola Outbreak Monitoring: Aethlon Medical is actively monitoring the Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda, preparing to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology, demonstrating the company's commitment to addressing public health crises.
Hemopurifier Treatment Efficacy: During the 2014 Ebola outbreak, the Hemopurifier was successfully administered to a critically ill patient, reducing their viral load from 400,000 to 1,000 copies per milliliter, with the virus becoming undetectable five days post-treatment, indicating the device's potential efficacy in emergency situations.
FDA Regulatory Pathway: The U.S. FDA has approved an Investigational Device Exemption for the Hemopurifier, establishing a regulatory pathway for its investigational use in Ebola-infected individuals in the U.S., highlighting the technology's potential in addressing life-threatening diseases.
Future Development Plans: Aethlon Medical stated it will continue to monitor the evolving Ebola situation and respond to inquiries from treating clinicians, emphasizing its strategic importance in combating viral threats where approved therapies may be limited.

Life Sciences Virtual Investor Forum Highlights Available On-Demand

Mar 13 2026Globenewswire

Forum Overview: The Life Sciences Virtual Investor Forum, held on March 11-12, showcased innovative companies from biotechnology, medical devices, and pharmaceuticals, providing investors with insights into emerging technologies and strategic growth opportunities, thereby attracting significant investor interest.
Presentation Access: Attendees can view forum presentations on-demand for 90 days, available 24/7, which enhances investor-company interaction and improves information transparency in the investment community.
1x1 Meeting Requests: Select companies are accepting management meeting requests through March 17, facilitating direct communication between investors and company executives, which strengthens investor relations management.
Enhanced Investor Engagement: Virtual Investor Conferences provide a real-time interactive platform that allows companies to connect more efficiently with investors, significantly increasing investor engagement and marking an innovation in investor communication methods.

Life Sciences Virtual Investor Forum Agenda Announced

Mar 10 2026Globenewswire

Agenda Announcement: Virtual Investor Conferences has announced the Life Sciences Virtual Investor Forum scheduled for March 11-12, 2026, inviting individual and institutional investors to participate for free, aiming to broaden the investor base and enhance company-investor interactions.
Company Presentation Schedule: The forum will feature presentations from several life sciences companies, including SeaStar Medical Holding Corporation and Nasus Pharma Ltd., with one-on-one management meetings arranged to facilitate direct communication of strategies to investors.
Platform Advantages: The Virtual Investor Conferences provide a real-time investor engagement solution that replicates the components of an on-site investor conference, enabling companies to access investors more efficiently and enhance presentation effectiveness, thereby increasing investor participation.
Focus on Industry Innovation: The forum highlights innovators in the life sciences sector, with the EVP of OTC Markets Group stating that the conference offers a unique opportunity for companies to engage with a broader investor audience, fostering strategic communication within the industry.